Spectrum granted US FDA reprieve on bioscan for Zevalin
This article was originally published in Scrip
Shares of Spectrum Pharmaceuticals rose as high as 6.8%, or 83 cents, on 21 November after the US FDA said the firm could remove from the labelling of the company's non-Hodgkin's lymphoma drug (NHL) Zevalin (ibritumomab tiuxetan) a requirement for a certain type of bioscan, known as an Indium-111 pretreatment imaging evaluation.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.